Neumora Therapeutics Aktie News

Günstige präklinische Daten für NMRA-215 gemeldet mit Plan, einen IND-Antrag im vierten Quartal 2026 einzureichen und bis Ende 2026 eine Phase‑1‑Studie zu beginnen

Das Unternehmen plant, im vierten Quartal 2026 einen IND-Antrag einzureichen und bis Ende 2026 eine Phase‑1-Studie zu starten Das Unternehmen plant, im vierten Quartal 2026 einen IND-Antrag einzureichen und bis Ende 2026 eine Phase‑1-Studie zu starten

Neumora Therapeutics said on ‌Monday it would stop developing its ​depression drug after ​two late-stage trials failed ⁠to meet their ​main goals.

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027...

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthc...

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 Strong financial position with $147.1 million in cash and cash equivalents expected to support oper...

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcar...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies